Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Aphton to acquire Igeneon

Dec. 17, 2004

Antibody therapy may enhance rituximab-mediated killing in non-Hodgkin's lymphoma

Dec. 17, 2004

Toll-like receptor agonist may be an effective immunotherapeutic approach to CLL

Dec. 17, 2004

Update on the efficacy and safety of MDX-060 in CD30-positive lymphoma

Dec. 16, 2004

Good tolerability profile found for DT388-IL-3 in AML

Dec. 16, 2004

FTC requests extension for review of MDX-010 collaboration

Dec. 14, 2004

First phase I/II data on the efficacy and safety of HuMax-CD20 in follicular lymphoma

Dec. 14, 2004

Swiss clearance for phase I study of 1D09C3

Dec. 13, 2004

Serono and Micromet sign collaboration and license agreement for MT-201

Dec. 13, 2004

Clinical responses seen in phase I/II study of Humax-CD20 in NHL

Dec. 10, 2004

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...